VAXART (VXRT): vaccino Coronavirus - Pagina 7
Ftse Mib ritraccia da livelli importanti, S&P 500 scende per le scadenze tecniche e la Fed che vuole anticipare i rialzi
Si apre all?insegna del ribasso la settimana borsistica con le Banche Centrali sempre protagoniste. Perdite generalizzate in chiusura della settimana precedente, specialmente nei settori legati al tema della reflazione, dopo …
Classifica rischi aziende 2021: ansia lockdown da pandemia sempre al top, anche con vaccini. Tra altre minacce attacchi cyber e debiti fuori controllo
Mai abbassare la guardia: anche se le vaccinazioni stanno consentendo la riapertura delle economie, e l’outlook per la crescita del Pil del 2021 è positivo, c’è ancora molto da fare …
Unicredit chiamata a reagire dopo settimana da -7%, gli short si accaniscono su Saipem. Situazione grafica ‘estrema’ per Tod’s
Al via una nuova settimana per i mercati, scossi venerdì scorso dalle parole di Bullard (Fed), che ha paventato la possibilità di un primo rialzo dei tassi già nel 2022, …
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #61
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    10,954
    Mentioned
    8 Post(s)
    Quoted
    1506 Post(s)
    Potenza rep
    42949692

    I Have a Dream

    che domani mi aprisse in Gap Up....VAXART (VXRT): vaccino Coronavirus-vxrt.jpg

  2. #62
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    10,954
    Mentioned
    8 Post(s)
    Quoted
    1506 Post(s)
    Potenza rep
    42949692
    Expect Vaxart Stock To Rise on a Unique Approach to Vaccinations

    Expect Vaxart Stock To Rise on a Unique Approach to Vaccinations
    Louis Navellier and the InvestorPlace Research Staff 4/27/2021
    RELATED QUOTES
    VXRT+3.90%▲


    The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.© Source: Ascannio / Shutterstock.com The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.
    Clinical-stage biotechnology company Vaxart (NASDAQ:VXRT), as the name implies, is known for developing vaccines. There are other, more famous coronavirus vaccine makers out there, but VXRT stock is cheap and might be worth considering for risk-tolerant investors.

    text, whiteboard: The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.© Provided by InvestorPlace The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.
    No one is going to claim that Vaxart was the first company to deliver a Covid-19 vaccine to the public. Yet, there’s more than one way to win the vaccine race.

    Pharmaceutical companies sometimes make a name for themselves by developing a product that’s different from all the others. Or they at least offer a new angle on an existing product.

    Now there’s data that strongly suggests that people want something different when it comes to Covid-19 vaccines. Could this give Vaxart an edge among vaccine makers? Let’s find out — but first, a quick stock-price analysis.


    VXRT Stock at a Glance
    Since the onset of the novel coronavirus last year, VXRT stock has been on a wild ride. So please, be prepared to accept some risk and only maintain small position sizes if you’re going to invest in this stock.

    At various times, this one might or might not be classified as a penny stock — defined by the U.S. Securities and Exchange Commission (SEC) as a stock that trades under $5 per share.

    This means that VXRT stock is low-priced, and it’s affordable for most portfolios. It has also been known to suddenly spike in price, so timing is everything when it comes to this stock.

    I’ll give you a couple of examples of what I’m talking about. In early June 2020, Vaxart shares were trading at $2 and change. But then, in mid-July, the stock price popped to $17.

    We saw something similar happen in January and February of this year, when VXRT stock leaped from $7 to a 52-week high of $24.90.

    On April 23, the stock settled slightly above the $5.50 level. The bulls will definitely want to defend this level and prevent Vaxart shares from sliding back into penny-stock territory.

    An Easy Pill to Swallow
    In case you didn’t get the memo, most people don’t like to be injected with a needle.

    They might view it as a necessity, though, as long as Covid-19 is still spreading and there aren’t any alternatives to needles. Still, it’s unpleasant to get an injection and sometimes it can cause discomfort and/or bruising.

    For some folks, the thought of getting a Covid-19 vaccine through an injection is so uncomfortable, that they might not get vaccinated at all.

    As Vaxart has reported, a national survey of 1,500 Americans over the age of 18, conducted by Quadrant Strategies, revealed that 23% of the respondents said that they don’t plan to get vaccinated.

    Yet, nearly one-third those currently refusing to get vaccinated, would get vaccinated if they could take a pill instead of getting an injection.

    Overcoming Resistance
    Not only that, but 7 in 10 of the respondents said they’d prefer to take a vaccine pill rather than getting injected with a vaccine.

    Amid that backdrop, it’s fair to say that Vaxart is well-positioned to capitalize on many people’s resistance to injections. After all, the company specializes in developing orally delivered vaccines.

    Vaxart typically produces its vaccines in tablet form. An advantage is that they can be stored and shipped without refrigeration.

    Moreover, Vaxart’s vaccine tablets can eliminate the risks associated with needle-stick injury. And, as the survey suggests, these tablets can help to overcome some people’s resistance to taking a Covid-19 vaccine.

    Not long ago, Vaxart completed its Phase 1 study of the VXA-CoV2-1 oral tablet coronavirus vaccine. The results were encouraging.

    Specifically, it was found that VXA-CoV2-1 “induced potent CD8+ T-cell responses that are potentially protective against the original as well as new and emerging Covid-19 strains.”

    The Takeaway
    Vaxart will never be known as being first to market with a Covid-19 vaccine. Nevertheless, there’s another way for the company to make its mark.

    The company could become known as a first mover in the field of orally administered Covid-19 vaccines. If so, then VXRT might never be a penny stock again.

    On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.

    Louis Navellier, who has been called “one of the most important money managers of our time,” has broken the silence in this shocking “tell all” video… exposing one of the most shocking events in our country’s history… and the one move every American needs to make today.

    Serenella, conosci questo Louis Navellier ? è uno che ci prende ?

  3. #63
    L'avatar di brunellobru
    Data Registrazione
    Oct 2011
    Messaggi
    2,157
    Mentioned
    0 Post(s)
    Quoted
    535 Post(s)
    Potenza rep
    42949682
    anche in italia stanno sperimentando il vaccino in pillole

    Google News -

  4. #64

    Data Registrazione
    Mar 2012
    Messaggi
    226
    Mentioned
    0 Post(s)
    Quoted
    95 Post(s)
    Potenza rep
    3807444
    È più promettente Ocugen con il suo Covaxin efficace contro tutte le varianti

  5. #65
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    10,954
    Mentioned
    8 Post(s)
    Quoted
    1506 Post(s)
    Potenza rep
    42949692
    Citazione Originariamente Scritto da Forex08 Visualizza Messaggio
    È più promettente Ocugen con il suo Covaxin efficace contro tutte le varianti
    il Covaxin si inietta non è una pillola

  6. #66
    L'avatar di serenella6
    Data Registrazione
    May 2009
    Messaggi
    10,116
    Mentioned
    11 Post(s)
    Quoted
    756 Post(s)
    Potenza rep
    42949685
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    Expect Vaxart Stock To Rise on a Unique Approach to Vaccinations

    Expect Vaxart Stock To Rise on a Unique Approach to Vaccinations
    Louis Navellier and the InvestorPlace Research Staff 4/27/2021
    RELATED QUOTES
    VXRT+3.90%▲


    The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.© Source: Ascannio / Shutterstock.com The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.
    Clinical-stage biotechnology company Vaxart (NASDAQ:VXRT), as the name implies, is known for developing vaccines. There are other, more famous coronavirus vaccine makers out there, but VXRT stock is cheap and might be worth considering for risk-tolerant investors.

    text, whiteboard: The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.© Provided by InvestorPlace The Vaxart (VXRT) logo is surrounded by face masks, syringes and pills.
    No one is going to claim that Vaxart was the first company to deliver a Covid-19 vaccine to the public. Yet, there’s more than one way to win the vaccine race.

    Pharmaceutical companies sometimes make a name for themselves by developing a product that’s different from all the others. Or they at least offer a new angle on an existing product.

    Now there’s data that strongly suggests that people want something different when it comes to Covid-19 vaccines. Could this give Vaxart an edge among vaccine makers? Let’s find out — but first, a quick stock-price analysis.


    VXRT Stock at a Glance
    Since the onset of the novel coronavirus last year, VXRT stock has been on a wild ride. So please, be prepared to accept some risk and only maintain small position sizes if you’re going to invest in this stock.

    At various times, this one might or might not be classified as a penny stock — defined by the U.S. Securities and Exchange Commission (SEC) as a stock that trades under $5 per share.

    This means that VXRT stock is low-priced, and it’s affordable for most portfolios. It has also been known to suddenly spike in price, so timing is everything when it comes to this stock.

    I’ll give you a couple of examples of what I’m talking about. In early June 2020, Vaxart shares were trading at $2 and change. But then, in mid-July, the stock price popped to $17.

    We saw something similar happen in January and February of this year, when VXRT stock leaped from $7 to a 52-week high of $24.90.

    On April 23, the stock settled slightly above the $5.50 level. The bulls will definitely want to defend this level and prevent Vaxart shares from sliding back into penny-stock territory.

    An Easy Pill to Swallow
    In case you didn’t get the memo, most people don’t like to be injected with a needle.

    They might view it as a necessity, though, as long as Covid-19 is still spreading and there aren’t any alternatives to needles. Still, it’s unpleasant to get an injection and sometimes it can cause discomfort and/or bruising.

    For some folks, the thought of getting a Covid-19 vaccine through an injection is so uncomfortable, that they might not get vaccinated at all.

    As Vaxart has reported, a national survey of 1,500 Americans over the age of 18, conducted by Quadrant Strategies, revealed that 23% of the respondents said that they don’t plan to get vaccinated.

    Yet, nearly one-third those currently refusing to get vaccinated, would get vaccinated if they could take a pill instead of getting an injection.

    Overcoming Resistance
    Not only that, but 7 in 10 of the respondents said they’d prefer to take a vaccine pill rather than getting injected with a vaccine.

    Amid that backdrop, it’s fair to say that Vaxart is well-positioned to capitalize on many people’s resistance to injections. After all, the company specializes in developing orally delivered vaccines.

    Vaxart typically produces its vaccines in tablet form. An advantage is that they can be stored and shipped without refrigeration.

    Moreover, Vaxart’s vaccine tablets can eliminate the risks associated with needle-stick injury. And, as the survey suggests, these tablets can help to overcome some people’s resistance to taking a Covid-19 vaccine.

    Not long ago, Vaxart completed its Phase 1 study of the VXA-CoV2-1 oral tablet coronavirus vaccine. The results were encouraging.

    Specifically, it was found that VXA-CoV2-1 “induced potent CD8+ T-cell responses that are potentially protective against the original as well as new and emerging Covid-19 strains.”

    The Takeaway
    Vaxart will never be known as being first to market with a Covid-19 vaccine. Nevertheless, there’s another way for the company to make its mark.

    The company could become known as a first mover in the field of orally administered Covid-19 vaccines. If so, then VXRT might never be a penny stock again.

    On the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.

    Louis Navellier, who has been called “one of the most important money managers of our time,” has broken the silence in this shocking “tell all” video… exposing one of the most shocking events in our country’s history… and the one move every American needs to make today.

    Serenella, conosci questo Louis Navellier ? è uno che ci prende ?



    Si Big , e' molto quotato negli Steizz, anche perche', nel corso degli anni e nella maggior parte dei casi, le sue intuizioni si sono dimostrate affidabili!

  7. #67
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    10,954
    Mentioned
    8 Post(s)
    Quoted
    1506 Post(s)
    Potenza rep
    42949692
    Citazione Originariamente Scritto da serenella6 Visualizza Messaggio
    Si Big , e' molto quotato negli Steizz, anche perche', nel corso degli anni e nella maggior parte dei casi, le sue intuizioni si sono dimostrate affidabili!
    Grazie Serenella, sempre utili i tuoi interventi

    l'hai già vsto questo video ?

    Oral COVID Vaccines - GAME CHANGERS - YouTube

  8. #68
    L'avatar di serenella6
    Data Registrazione
    May 2009
    Messaggi
    10,116
    Mentioned
    11 Post(s)
    Quoted
    756 Post(s)
    Potenza rep
    42949685
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    Grazie Serenella, sempre utili i tuoi interventi

    l'hai già vsto questo video ?

    Oral COVID Vaccines - GAME CHANGERS - YouTube

    La cosa e' reciproca , grazie anche a te, che posti sempre informazioni utili..oltre ai grafici!

    Non l'ho visto il video , ma , lo guardero' piu' tardi..ora is Drink Time e poi cena

    A domani..Grazie

  9. #69
    L'avatar di pierlala
    Data Registrazione
    Jun 2017
    Messaggi
    1,095
    Mentioned
    0 Post(s)
    Quoted
    499 Post(s)
    Potenza rep
    23782417
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    è tornata al prezzo di carico, oggi ne ho prese ancora un pò nella speranza che possa uscire qualche buona nuova dal World Vaccine Congress Washington
    Ciao Big...da quello che leggo sicuramente sempre dentro...volevo chiederti se long term tipo IMMP (almeno da quello che mi è sembrato di capire nel TD appropriato)...
    Grazie

  10. #70
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    10,954
    Mentioned
    8 Post(s)
    Quoted
    1506 Post(s)
    Potenza rep
    42949692
    No su questa non vado long

Accedi